Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tiziana

- PMLiVE

NHS rolls out artificial pancreas for adults and children with type 1 diabetes in England

Type 1 diabetes accounts for approximately 10% of all diabetes cases in the UK

- PMLiVE

Two KCL research projects awarded £4.8m to help find cure for type 1 diabetes

The Type 1 Diabetes Grand Challenge has awarded six research projects grants totalling £13m

- PMLiVE

Eli Lilly to acquire Sigilon in deal worth over $300m

The companies have been working together since 2018 on cell therapies for type 1 diabetes

- PMLiVE

FDA approves CellTrans’ Lantidra as first cellular therapy to treat type 1 diabetes

The therapy is indicated for use in patients who are unable to meet their target blood glucose levels

- PMLiVE

Tiziana to develop intranasal foralumab for type 1 diabetes

Approximately 4.7 million people in the UK are currently living with diabetes

- PMLiVE

Sanofi to acquire Provention Bio in deal worth $2.9bn

The merger includes recently-approved type 1 diabetes prevention therapy Tzield

- PMLiVE

Tidepool’s automated insulin dosing app for type 1 diabetes gets FDA approval

Tidepool Loop is the first app of its kind to receive clearance in the US

- PMLiVE

FDA approves first drug to delay onset of type 1 diabetes

Provention Bio’s Tzield delayed the average onset of type 1 diabetes by over four years

- PMLiVE

University of Birmingham to launch type 1 diabetes trial for at-risk children

Blood tests will identify those deemed most likely to develop the condition

- PMLiVE

NHS England to roll out continuous glucose monitors to all those with type 1 diabetes

The wearable monitor sends information to a mobile app, allowing those with diabetes to easily keep track of their glucose levels at all times

- PMLiVE

Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes

Vertex has released results from its phase 1/2 trial for VX-880, a stem-cell-derived therapy that restores insulin production

- PMLiVE

Vertex expands further into cell and genetic therapies with a deal worth up to $1.2bn

A new deal will see Vertex harness Arbor Biotechnologies gene-editing technology to enhance its discovery efforts

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links